Country of origin - Poland, ICN Polfa Rzeszow Poland, Polfa Poland
Pharm-Group - Products containing fluoride
Manufacturers - Polfa, Rzeszowskie Zaklady Farmaceutyczne SA (Poland), ICN Polfa Rzeszow (Poland), Polfa (Poland)
International name - Sodium fluoride
Synonyms - ACT, Coreberon, Sodium fluoride, Ossin
Dosage forms - lozenges 1 mg
Compound:
Active substance: Sodium fluoride.
Indications for use:
Osteoporosis: primary (postmenopausal, presenile, senile, idiopathic), steroid (prevention and treatment); local osteopathies, caries prevention in children and adults.
Contraindications:
For systemic use: severe renal or liver dysfunction, exacerbation of gastric or duodenal ulcers, pregnancy, breastfeeding, children under 6 months, 3 years, 6 or 14 years (depending on the dosage form and dose).
Side effect:
With systemic use: dyspeptic symptoms, pain in the lower extremities and joints, increased fatigue, weakness, headache, osteosclerosis, ectopic calcification (especially when combined with vitamin D or A), hypothyroidism, idiosyncrasy, allergic reactions (skin rash, etc.) .
Interaction:
Calcium, magnesium and aluminum ions slow down absorption (forming poorly soluble compounds). Antacids reduce effectiveness (it is recommended to use them 2 hours before taking sodium fluoride). Vitamins A and D promote ectopic calcification.
Overdose:
Symptoms: lacrimation, hypersalivation, nausea, anorexia, bloody diarrhea and vomiting, pain in the abdomen, lower extremities and joints, constriction of the pupils, blurred vision, weakness, myasthenia gravis, tremor, convulsions, hyperthermia, increased heart rate, hypotension; Possible death.
Special instructions:
An intermittent course of treatment is recommended if arthralgia occurs during continuous drug therapy. Use in children under 6 years of age requires special monitoring. In patients with blood diseases, regular blood tests are recommended during therapy. During systemic use, it is necessary to conduct an annual X-ray examination to assess the effectiveness of therapy and decide whether to continue treatment, as well as for early detection of fluorosis. When choosing a dose of the drug, the fluoride content in drinking water should be taken into account. To achieve adequate mineralization of bone tissue, it is necessary to additionally ensure the intake of calcium and magnesium into the body. An increase in the level of alkaline phosphatase indicates the development of the effect.
Literature:
Encyclopedia of Medicines, 2004.